How Cybernet's CyberMed G22 Powers the Infrastructure Behind a Historic Cancer Therapy

Iovance's therapeutic model is unlike anything in conventional pharmaceutical manufacturing. A tumor sample is surgically removed from a patient and shipped overnight to the Iovance Cell Therapy Center (iCTC) in Philadelphia a 136,000-square-foot facility purpose-built for this work. There, tumor-infiltrating lymphocytes (TIL), the patient's own immune cells, are isolated, amplified, and reinvigorated through a proprietary process before being shipped back for a single, personalized infusion. Every patient is their own manufacturing run.

That reality places extraordinary demands on every system in the building. On the manufacturing floor, the iCTC operates under FDA Good Manufacturing Practice (GMP) regulations where particulate control, validated equipment, and uninterrupted uptime aren't operational preferences they're regulatory requirements. Fans pushing air through computer chassis create contamination risks. Hardware that requires downtime for maintenance has no place in a facility running time-critical, patient-specific batches. And revalidating computing equipment mid-production carries real compliance cost which means hardware longevity and model consistency aren't conveniences, they're procurement necessities.

At the same time, Iovance's clinical workflows demand the same medical-grade foundation: safe, certified equipment in patient-proximate environments, surfaces that withstand aggressive chemical disinfection, and systems that integrate cleanly with the facility's broader operations.
The challenge was finding a single platform that could satisfy both environments without compromise.

Iovance standardized on Cybernet's CyberMed G22 medical panel PC deploying it across both their GMP manufacturing environment and their clinical workstation operations throughout the iCTC.

The decision reflects what purpose-built medical hardware actually means in practice. The CyberMed G22's fanless, sealed design eliminates particulate movement in sensitive manufacturing spaces. Its IP65-rated front bezel withstands the aggressive chemical disinfection protocols that both GMP and clinical environments demand, without degrading over repeated cleaning cycles. IEC 60601-1 medical certification ensures it meets the safety standards required in patient-proximate and regulated spaces. Imprivata-certified single sign-on keeps staff moving efficiently without compromising data security across shared workstations.

And critically, Cybernet's commitment to manufacturing the same model for a minimum of five years means Iovance can standardize on a validated platform without facing forced hardware transitions that would trigger requalification a significant operational and compliance consideration for any FDA-regulated facility.

The CyberMed G22 continues to serve as Iovance's computing platform of choice across their iCTC facility, supporting the manufacturing and delivery of Amtagvi as Iovance expands its patient reach and advances clinical trials in additional solid tumor indications including non-small cell lung cancer.

The dual deployment spanning both regulated manufacturing and clinical workflows reflects something more meaningful than a single successful installation. It reflects a platform trusted at every layer of one of medicine's most consequential supply chains.

"When you're working in an environment where computing infrastructure touches both an FDA-regulated manufacturing process and direct patient care workflows, there is no room for two different hardware standards," said Ali Bagheri, Senior Vice President of Global Operations at Cybernet. "Iovance chose a single platform that performs across both. That's exactly what the CyberMed G22 was built to do."